Uncategorized
Hemovent Starts GLP in vivo Trial for Long-Term Use of Its Next-Gen ExtraCorporeal Membrane Oxygenation (ECMO) System
AACHEN, Germany--(BUSINESS WIRE)--Hemovent GmbH announced today that it has commenced a GLP in vivo study for the long-term (7 days) use of its novel and portable artificial lung technology platform, designed for a wide range of indications from ExtraCorporeal CO2 Removal (ECCO2R) to ExtraCorporeal Life Support (ECLS). These types of applications are also referred to as ExtraCorporeal Membrane Oxygenation (ECMO): the establishment of an artificial external blood circuit with a portable pump and